• Ritesh Agarwal, Sahajal Dhooria, Singh Sehgal Inderpaul I Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Ashutosh N Aggarwal, Mandeep Garg, Biman Saikia, Digambar Behera, and Arunaloke Chakrabarti.
• Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: agarwal.ritesh@outlook.in.
• Chest. 2018 Mar 1; 153 (3): 656-664.

ObjectiveWhether itraconazole monotherapy is effective in the acute stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown. The goal of this study was to compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA.MethodsTreatment-naive subjects with ABPA complicating asthma (January 2012 to December 2013) were randomized to receive either oral itraconazole or prednisolone for 4 months. The study was not blinded. The primary outcomes were proportion of subjects exhibiting a composite response after 6 weeks, percent decline in IgE after treatment, and numbers of subjects experiencing exacerbation. The secondary outcomes included the time to first exacerbation, change in lung function, and treatment-related adverse effects.ResultsA total of 131 subjects (prednisolone group, n = 63; itraconazole group, n = 68) were included in the study. The number of subjects exhibiting a composite response was significantly higher in the prednisolone group compared with the itraconazole group (100% vs 88%; P = .007). The percent decline in IgE after 6 weeks and 3 months and the number of subjects with exacerbations after 1 and 2 years of treatment were similar in the two groups. The time to first exacerbation (mean: 437 vs 442 days) and the improvement in lung function after 6 weeks was also similar in the two groups. The occurrence of side effects was significantly higher in the glucocorticoid arm (P < .001).ConclusionsPrednisolone was more effective in inducing response than itraconazole in acute-stage ABPA. However, itraconazole was also effective in a considerable number and, with fewer side effects compared with prednisolone, remains an attractive alternative in the initial treatment of ABPA.Trial RegistryClinicalTrials.gov; No.: NCT01321827; URL: www.clinicaltrials.gov).Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

32 keywords...

hide…